SLXN — Silexion Therapeutics Balance Sheet
0.000.00%
- $8.69m
- $11.47m
Annual balance sheet for Silexion Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Cash and Equivalents | |||
Cash and Short Term Investments | 8.26 | 4.59 | 1.19 |
Prepaid Expenses | |||
Total Other Current Assets | |||
Total Current Assets | 8.84 | 4.98 | 2.25 |
Gross Property, Plant And Equipment | |||
Accumulated Depreciation | |||
Net Property, Plant And Equipment | 0.464 | 0.247 | 0.56 |
Other Long Term Assets | |||
Total Assets | 9.33 | 5.26 | 2.86 |
Accounts Payable | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Total Other Current Liabilities | |||
Total Current Liabilities | 1.61 | 2.2 | 3.52 |
Long Term Debt | |||
Total Long Term Debt | |||
Total Debt | |||
Minority Interest | |||
Total Other Liabilities | |||
Total Liabilities | 5.35 | 5.67 | 6.85 |
Redeemable Preferred Stock | |||
Non Redeemable Preferred Stock | |||
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Total Equity | 3.98 | -0.419 | -3.99 |
Total Liabilities & Shareholders' Equity | 9.33 | 5.26 | 2.86 |
Total Common Shares Outstanding |